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Abstract 
Objective 
Growing awareness that symptoms of autism spectrum disorder (ASD) transcend multiple 
diagnostic categories, and major advances in the identification of genetic syndromes associated with 
ASD, has led to widespread use of ASD symptom measures in etiological studies of 
neurodevelopmental disorders. Insufficient consideration of potentially confounding factors such as 
cognitive ability or behavior problems can have important negative consequences in interpretation 
of findings, including erroneous estimation of associations between ASD and etiological factors.  
Method 
Participants were 388 children aged 2-13 years with diagnoses of ASD or another 
neurodevelopmental disorder without ASD. Receiver operating characteristics methods were used 
to assess the influence of IQ and emotional/behavioral problems on the discriminative ability of 
three widely used ASD symptom measures; the Social Responsiveness Scale (SRS), the Autism 
Diagnostic Interview-Revised (ADI-R), and the Autism Diagnostic Observation Schedule (ADOS).  
Results  
IQ influenced the discriminative thresholds of the SRS and ADI-R, and emotional/behavioral 
problems affected the discriminative thresholds of the SRS, ADI-R, and ADOS. This resulted in 
low specificity of ASD cut-offs on the SRS and ADI-R for children with intellectual disability 
without ASD (27-42%), and low specificity across all three instruments for children without ASD 
with elevated emotional/behavioral problems (36-59%). Adjustment for these characteristics 
resulted in improved discriminative ability for all three ASD measures. 
Conclusion 
The findings indicate that scores on ASD symptom measures reflect far more than ASD symptoms. 
Valid interpretation of these measures requires steps to account for the influences of IQ and 
emotional/behavioral problems. 
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Introduction 
Numerous standardized instruments designed to measure symptoms of autism spectrum 
disorders (ASD) have been developed during the past two decades. These instruments have had a 
major influence on the field, changing the way that ASD assessments are conducted for clinical and 
research purposes across many parts of the world. The use of ASD symptom measures has extended 
to a wide range of populations with complex behavioral presentations, as awareness has grown 
about the frequent co-occurrence of ASD, or ASD symptoms, with other disorders. In clinical 
settings, standardized instruments are commonly used to assess ASD symptoms among children 
with medical, developmental, and psychiatric concerns not specific to ASD.1, 2 Current practice 
parameters recommend routine screening for symptoms of ASD as part of general child psychiatric 
and developmental assessments, and comprehensive diagnostic evaluation for ASD if symptoms are 
detected.3 There has also been a surge in research studies using standardized instruments to 
determine the prevalence and correlates of ASD in individuals with a range of psychiatric diagnoses 
(e.g., ADHD) and neurogenetic syndromes (e.g., Fragile X syndrome, Cornelia de Lange 
syndrome).4-8 
A foundational assumption is that scores on ASD symptom measures actually reflect 
symptoms of ASD; higher or lower scores are thought to correspond to higher or lower levels of 
ASD symptomatology. However, concerns have been raised that factors not specific to ASD, such 
as cognitive impairments and emotional/behavioral problems can lead to artificially inflated scores 
on ASD symptom measures.4, 9-13 For example, impulsivity and hyperactivity may be manifested as 
inappropriate social approaches or repetitive behaviors, anxiety and mood problems as social 
avoidance or inflexibility, and intellectual disability as age-inappropriate peer interactions or 
interests.  
Due to the challenges inherent in differentiating ASD symptoms from other developmental, 
emotional and behavioral problems, best practices dicate that ASD diagnosis be based on expert 
clinician judgment, informed by all available data from a comprehensive assessment including 
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multiple sources of information and standardized instruments.3, 14, 15 Nevertheless, the ways in 
which individual characteristics such as IQ and emotional/behavioral problems influence agreement 
between ASD symptom measures and clinical best-estimate diagnosis are not well understood.  
Additionally, in research studies, ASD symptom scores are commonly analyzed without properly 
considering how individual characteristics might affect score distributions.4-6, 16-22  
Insufficient attention to factors influencing ASD symptom measures can have important 
negative consequences, both in clinical service contexts (e.g., misdiagnoses, loss of time for 
appropriate interventions) and research (e.g., inflated prevalence rates, erroneous estimation of the 
strength of associations between ASD symptoms and etiological factors). As the composition of 
clinical referral and research populations continues to evolve, a thorough understanding of how 
individual characteristics affect the discriminative ability of ASD symptom measures becomes 
critical.23, 24  
The purpose of the current study was to examine how cognitive ability (IQ) and 
emotional/behavioral problems (EBP) influence the discriminative ability of three widely used ASD 
symptom measures; the Social Responsiveness Scale (SRS)25, 26, the Autism Diagnostic Interview-
Revised (ADI-R)27, and the Autism Diagnostic Observation Schedule (ADOS)28, 29. While absolute 
differences in discriminative accuracy between the instruments would be expected due to method 
variance (e.g., length, format, informant), the main goal was to investigate the influence of IQ and 
EBP on discriminative ability within and across multiple ASD measures. Discriminative ability can 
be affected in various alternative or complementary ways, with implications for interpretation of 
ASD symptom scores. For example, if cognitive ability is comparably associated with elevated 
ASD symptom scores in children both with and without ASD, this will only affect the validity of 
specific thresholds and not the overall discriminative capacity of the ASD measure. Thus, 
reasonable steps could be taken to adjust for IQ-related differences in discriminative thresholds. 
However, it is also possible that cognitive ability is differentially associated with ASD symptom 
scores among children without ASD than in children with ASD, thereby compromising the inherent 
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capacity of the measure to distinguish between these groups. We aimed to assess both forms of 
covariate influence on the discriminative abilities of the ASD measures in a sample of children with 
ASD and a control group of children with other neurodevelopmental disorders without ASD.  
 
Methods and Materials 
Participants 
 Participants included in the current analyses were assessed as part of a study aiming to 
validate an ASD screening interview.30 The sample consisted of 407 children aged 2-13 years who 
were recruited from two clinics based on previous diagnosis of ASD or another neurodevelopmental 
disorder without ASD (i.e., ADHD, language disorders, intellectual disability and/or early 
developmental delays, or mood/anxiety disorders). The only exclusion criteria were known genetic 
syndromes, or severe sensory (i.e., blindness, deafness) or motor impairments (i.e., not walking) 
that would render the administration of certain instruments invalid. For the present analyses, 19 
children were excluded due to not fulfilling criteria for any DSM-IV-TR diagnosis (n=10), or not 
having measures of IQ (n=1) or parent-rated emotional/behavioral problems (n=8). Therefore, the 
final sample consisted of 388 children with best-estimate clinical diagnoses of ASD (n=225) or 
other neurodevelopmental disorders without ASD (n=163; ADHD n=62, language disorder n=48, 
intellectual disability n=26, mood/anxiety disorder n=27). Sample characteristics are presented in 
Table 1. Co-occurring diagnoses were assigned to 54.7% of children in the ASD group and 29.5% 
of children in the non-ASD group (Table S1, available online).  
Participants were recruited through clinic referral/intake, professional referral, and flyers or 
website communication, either from the Divisions of Developmental and Behavioral Pediatrics and 
Behavioral Medicine and Clinical Psychology at a large Children´s hospital in Ohio, or at a 
university-based clinic specializing in ASD in Michigan. The majority of study participants with 
ASD were seen at the ASD specialty clinic (80.0%; n=180 of 225), whereas most of the non-ASD 
participants were seen at the Children´s hospital (88.3%; n=144 of 163). The Institutional Review 
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Boards at the respective sites approved study procedures, and caregivers provided informed consent 
prior to participation.  
TABLE 1 
 
Measures 
The SRS25 is a 65-item parent-completed questionnaire designed to measure ASD symptoms 
in 4-18 year-old children (applicable to 319 of 388 participants in the current study). The raw total 
(range 0-195) was used in analyses of continuous SRS scores. The SRS-Second Edition (SRS-2)26 
is equivalent to the original SRS for this age group, and provides T scores and cutoffs for clinically 
significant ASD symptoms according to population-based norms by age and sex (Mild range=T≥60, 
Moderate range=T≥66, Severe range=T≥75). The SRS-2 Moderate and Severe cutoffs were used in 
the present analyses, as scores in the Mild range are reported to have less discriminative utility. 26  
The ADI-R27 is a standardized caregiver interview that collects information about both past 
and current ASD symptoms. In order to examine continuous ADI-R scores based on current 
symptoms, as for the SRS and the ADOS, ADI-Current total scores (range 0-64) were used. ADI-
Current comprised the sum of scores from ADI-R items that have been mapped to DSM-5 criteria 
in previous studies.7, 31 The ADI-R formal classification of autism (i.e., Autistic Disorder), as well 
as criteria recommended for classifying broader ASD,32 are based on past behavior items from the 
diagnostic algorithm. Therefore, results of analyses are also reported for the total sum of diagnostic 
algorithm items (ADI-diagnostic, range 0-68).  
The ADOS is a clinician-administered observational assessment designed to elicit behaviors 
relevant to the diagnosis of ASD at particular ages and developmental levels.11, 28, 29 The ADOS-2 
algorithm raw total (range 0-28) and calibrated severity scores (CSS, standardized according to age 
and language level) were calculated. Raw totals are used to generate classifications of autism, ASD, 
and non-ASD. The raw totals were used when examining continuous ADOS scores given the 
restricted range (1-10) of the CSS. In addition to items measuring ASD-related behaviors, the 
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ADOS includes ratings of over-activity, aggressive behavior, and anxiety that occurred during the 
ADOS session (“other abnormal behaviors”, not included in the ASD algorithm).28 The sum of 
these three items was used to measure clinician-observed emotional/behavioral problems (EBP-
ADOS, range 0-6).  
Parent-rated emotional/behavioral problems were measured by the Internalizing and 
Externalizing Problems scales from the Child Behavior Checklist (CBCL).33, 34 T scores of 64 or 
higher are in the clinical range. Table 1 shows the proportions of children with clinical-range 
emotional/behavioral problems. Nonverbal IQ (NVIQ) was used as a continuous measure of 
cognitive ability, measured with standard scores from the Differential Ability Scales-II35 (DAS-II; 
n=330), or ratio scores (mental age/chronological age*100)36 from the Mullen Scales of Early 
Learning37 (MSEL; n=58). Among the children without ASD, 26 (16.0%) were diagnosed with 
intellectual disability (ID). NVIQ below 70 was used to define intellectual disability in children 
with ASD (n=72, 32.0%).   
 
Procedure 
 The study assessment protocol included  questionnaires (CBCL, SRS), parent interview 
(ADI-R, Vineland-II38), and direct child assessment (cognitive and language testing, ADOS, self-
report questionnaires for older, verbal children) (see 30). The ADOS and ADI-R were administered 
by experienced clinicians who had demonstrated research reliability on the instruments, and 
reliability was continuously monitored within and across the two sites. There was always at least 
one Ph.D. level clinical psychologist assigned to each case. Clinicians were blinded to the 
diagnostic status or other previous information about the participant. To maintain blindness during 
the assessment protocol, the parent interview and child assessment were conducted by different 
clinicians whenever possible (72% of cases). In accordance with current best practices for 
diagnosing ASD,3, 14, 39 consensus clinical judgment informed by all information obtained during 
the evaluation was used to assign a best-estimate diagnosis (DSM-IV-TR criteria). Total/algorithm 
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scores from the SRS, ADI-R, and ADOS were not calculated until after the diagnosis had been 
assigned, but the clinicians reviewed all other information from the assessment (including 
qualitative and item-level information elicited from these instruments).  
 
Data analyses  
All analyses were undertaken in Stata 13 (Statacorp, 2013), in parallel for the SRS (raw), the 
ADI-R (current and diagnostic), and the ADOS (raw). Emotional/behavioral problems were 
examined both as rated by parents (CBCL-Internalizing and CBCL-Externalizing) and clinicians 
(EBP-ADOS) because previous research suggests that these problems are often context-specific, 
with modest associations across rating contexts.40 In the total sample, EBP-ADOS (sum of the non-
algorithm items of over-activity, anxiety and aggressive behavior) correlated significantly with 
CBCL-Externalizing (0.15, p=003), but not with CBCL-Internalizing (r=0.06, p=0.27). Child´s age 
and sex have been found to be associated with both ASD symptoms and emotional/behavioral 
problems,41, 42 and were therefore included in all analyses. Assessment site and racial composition 
(which was associated with site) differed between the ASD and non-ASD diagnostic groups, but 
were not included in the models given no significant associations with ASD instrument scores when 
accounting for diagnosis, and no interaction effects of site/race and diagnosis (all p>0.05).  
ROC analysis is a well-established method of assessing the discriminative ability of a 
continuously scored instrument compared against a dichotomously defined gold standard (e.g., 
clinical diagnosis).43 The ROC curve is a plot of the true positive rate, the proportion of individuals 
with ASD correctly classified as ASD, against the false positive rate, the proportion of individuals 
without ASD misclassified by the instrument as ASD, across the full range of possible thresholds 
(i.e., cut-offs). In assessment of the discriminative ability of ASD instruments, confounding occurs 
when a covariate such as IQ is associated both with instrument scores and diagnostic group. For 
example, if lower IQ is associated with higher scores on an ASD instrument, then discriminative 
ability will be overestimated when mean IQ is lower in the ASD group than in the control group.  
  
 
10 
Pepe and colleagues have developed methods to assess the influence of covariates on the 
discriminative ability of instruments.43, 44 The first step is to examine whether the covariate is 
associated with scores on the instrument in the control group, thereby affecting the threshold (i.e., 
cut-off) of optimal separation between ASD cases and non-ASD controls. Thus, we used multiple 
linear regression analysis with NVIQ, emotional/behavioral problems, age and sex entered as 
predictors of scores on each ASD instrument (SRS, ADI-R, ADOS) (Table 2). Power analysis 
showed at least 80% power for the detection of small associations (η2p≥ 0.01; Cohen´s f≥0.10) (6 
predictors, α < .05, smallest subsample n=142). The second step is to assess whether the covariate is 
associated with the overall separation (i.e., the ROC curve) between ASD cases and non-ASD 
controls, above and beyond a need to use covariate-adjusted thresholds. ROC regression methods 
were used to test this, using the Stata procedure rocreg with the linear covariate adjustment option 
(Table 3).   
In all regression analyses, the continuous predictors (i.e., NVIQ, emotional/behavioral 
problems, age) were centered at the mean, and bootstrapping was used for robust estimation of 
standard errors and confidence intervals (1,000 resamples). Significance level was set at α < .05 
(two-tailed), using raw p values given that all analyses were planned. We also report the p values 
adjusted for the false discovery rate45 (denoted as q values). As measures of effect size, we report 
partial eta squared (η2p, small: 0.01-0.05, medium: 0.06-0.13, large: ≥0.14) from multiple linear 
regression analyses, and sensitivity, specificity and area under the curve (AUC) scores from ROC 
analyses. Pearson´s correlations showing the bivariate associations among the child characteristics 
and the ASD instruments are presented in Table S2, available online. 
 
Results 
Influence on discriminative thresholds 
 The multiple linear regressions showed that lower NVIQ among children without ASD was 
associated with elevated scores on the SRS (η2p=0.16, q<0.01) and the ADI-R (ADI-diagnostic 
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η2p=0.09, q<0.01; ADI-current η2p=0.04, q=0.05), but not on the ADOS (Table 2). Thus, the 
specificity of the SRS and ADI-R was dependent on NVIQ. When comparing children with and 
without intellectual disability, specificity was 27% versus 65% for the SRS (Moderate cutoff), 42% 
versus 71% for the ADI-R (ASD cutoff), and 77% versus 76% for the ADOS (ASD cutoff) (see 
confidence intervals in Table 4).  
Emotional/behavioral problems were associated with elevated scores on all three ASD 
measures, although the particular associations varied according to the rating context. Parent-rated 
EBP were associated with elevated scores on the parental report-based SRS (CBCL-Internalizing 
η2p=18, q<0.01; CBCL-Externalizing η2p=18, q<0.01) and ADI-R (CBCL-Internalizing: ADI-
current η2p=07, q<0.01, ADI-diagnostic η2p=04, q=0.05; CBCL-Externalizing: ADI-current 
η2p=0.03, q=0.05, ADI-diagnostic η2p=02, q=0.17). When comparing children with and without 
clinically significant parent-rated EBP, specificity of the SRS (Moderate cutoff) was 36-39% versus 
68-75%, and specificity of the ADI-R (ASD cutoff) was 56-59% versus 72%. Clinician-observed 
EBP were not significantly associated with scores on these parental report-based ASD measures 
over and above parent-rated EBP (Table 2).  
Parent-rated EBP were not associated with scores on the clinician observation-based ADOS, 
and fairly stable specificity was found across subgroups differing in parent-rated EBP (75-78%). In 
contrast, clinician-observed EBP were significantly associated with elevated ADOS scores 
(η2p=0.05, q<0.05) (Table 2). When comparing children with and without marked 
emotional/behavioral problems as observed by clinicians, specificity was 56% versus 83% for the 
ADOS (ASD cutoff), 51% versus 72% for the ADI-R (ASD cutoff), and 41% versus 63% for the 
SRS (Moderate cutoff).  
In addition to NVIQ and EBP, the child´s age was associated only with the discriminative 
threshold of the ADI-R (ADI-current η2p=0.11, q<0.01, ADI-diagnostic η2p=0.06, q<0.01), such that 
younger age was associated with elevated ADI-current scores among children without ASD. The 
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child´s sex was not significantly associated with the discriminative threshold of any of the ASD 
measures.  
TABLE 2 
TABLE 3 
 
Influence on overall discriminative capacity (the ROC curve) 
The multiple regression analyses above examined whether the covariates (i.e., NVIQ and 
EBP) were associated with shifted distributions of ASD instrument scores, suggesting the need for 
covariate-adjusted thresholds. ROC regression tested whether the covariates were associated with 
the inherent capacity of the instruments to separate between children with and without ASD when 
using covariate-adjusted thresholds. Table 3 presents the regression coefficients of the covariates on 
the ROC curve for each of the ASD instruments (SRS, ADI-R and ADOS). Neither NVIQ nor EBP 
were found to significantly affect the ROC curve of any of the three ASD measures. As shown in 
Table 4, subgroups stratified by level of NVIQ and EBP had AUC scores with overlapping 
confidence intervals, and the reductions in specificity associated with intellectual disability (SRS, 
ADI-R) and elevated EBP (SRS, ADI-R, ADOS) were generally accompanied by increases in 
sensitivity. Figure 1 illustrates that the score distributions on the ASD measures were shifted 
according to level of EBP in both the ASD and non-ASD diagnostic groups (EBP are shown by 
parent-rating for the SRS and ADI-R and by clinician-observation for the ADOS because these 
were significantly associated; other combinations are shown in Figure S1, available online).   
FIGURE 1 
The child´s sex was not significantly associated with the ROC curve of any of the ASD 
measures (Table 3). However, child age was found to be significantly associated with the ROC 
curve of the ADI-R (ADI-diagnostic coefficient=0.21, 95% CI=0.11,0.31, q<0.01¸ ADI-current 
q=0.06), such that ADI-R scores showed increased accuracy for ASD in older compared to younger 
children.  
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Sensitivity analyses 
Results for the ADI-R and ADOS were similar when restricting the sample to children who 
also had completed the SRS (i.e., age 4 years or older). Results were also very similar when using 
the ADOS calibrated severity scores instead of the raw scores, or when using full scale or verbal IQ 
instead of NVIQ. Controlling for clinic site did not affect the results. Due to high correlations 
between NVIQ and continuous measures of language functioning (r=0.64 with Vineland Expressive 
Communication), we could not adequately address language as an additional factor. However, 
adjusting for whether children had attained fluent speech (i.e., whether or not they were capable of 
completing Module 3 of the ADOS) did not affect the findings, and this measure of language level 
was not significantly associated with the ASD measures beyond IQ. Given that CBCL-Internalizing 
covers withdrawn behaviors that may overlap with core ASD symptoms, we re-analyzed the data 
using CBCL-Anxiety, with very similar findings. Measurement of EBP by parental interview (i.e., 
ADI-R current aggressive behavior) instead of the questionnaire-based CBCL also resulted in 
similar results (significant medium sized associations with discriminative thresholds only for the 
SRS and ADI-R, non-significant associations with ROC curves). Medication use was not 
significantly associated with ASD symptom scores, and did not affect any of the models tested. The 
results of these analyses are available upon request. 
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Discussion 
This study provides several insights into the performance of ASD symptom measures when 
used with children with differing levels of cognitive ability and emotional/behavioral problems 
(EBP). To our knowledge, this is the first study to examine the influence of individual 
characteristics on several ASD measures based on multiple sources of information, and to use a 
control group with non-ASD neurodevelopmental disorders who had undergone careful assessment 
to rule out ASD. The results indicate that the discriminative abilities of three commonly used ASD 
measures (the SRS, ADI-R, and ADOS) are substantially affected by individual characteristics 
beyond ASD symptoms. Among children without ASD, lower NVIQ and more parent-rated EBP 
were significantly associated with elevated scores on the SRS and ADI-R, while clinician-observed 
EBP were significantly associated with elevated scores on the ADOS. The established instrument 
cutoffs for ASD showed low specificity among children with intellectual disability (SRS, ADI-R), 
elevated parent-rated EBP (SRS, ADI-R), and elevated clinician-observed EBP (SRS, ADI-R, 
ADOS).  
We found that NVIQ was less associated with the discriminative threshold of the ADOS 
than of the SRS or ADI-R. This could be partially explained by the fact that ADOS administration 
and coding procedures are specifically designed to take developmental level into account (i.e., 
through the use of a Module system).11 In line with previous studies,12, 46, 47 parent-rated EBP 
affected the threshold validity of parental report-based ASD measures (SRS, ADI-R), but not the 
clinician observation-based ADOS. The present study extends these findings by demonstrating that 
clinician-observed EBP significantly influenced discriminative thresholds on the ADOS. This 
highlights the importance of considering the context and informant in assessment of relationships 
between ASD symptoms and other psychiatric symptoms or behavior problems. Further study using 
an independent measure of clinician-observed EBP is needed in order to clarify their influence on 
the validity of the ADOS and other ASD symptom measures.  
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For all three ASD measures, adjustment for the influence of NVIQ and EBP on the 
discriminative threshold resulted in stable discriminative accuracy among children with differing 
levels of cognitive ability and behavior problems. For example, the ASD measures provided similar 
discriminative ability for ASD among children with low versus elevated EBP (Figure 1). However, 
much weaker differentiation was found when comparing children with ASD and low EBP to 
children without ASD and elevated EBP. Notably, SRS scores did not distinguish between these 
subgroups. These findings illustrate the potential danger of making unadjusted comparisons of ASD 
symptom scores between children who vary with respect to EBP or IQ. The results also lend 
support to earlier recommendations that reasonable steps could and should be taken to facilitate 
more valid interpretation of scores on ASD measures,10, 12, 48 such as using scores and thresholds 
standardized according to IQ or EBP, or applying statistical adjustment.  
The use of scores from ASD measures without adequately considering the influence of other 
child-level variables remains widespread. Studies of genetic syndromes often report the proportions 
of children meeting ASD instrument cutoffs without taking IQ or EBP into account.4, 6, 16-18 
Unadjusted comparisons of ASD symptom scores are also commonly made between children with 
ASD and children with other psychiatric disorders or genetic syndromes who differ significantly on 
these variables.4, 5, 19 Furthermore, many studies assessing the relationships between ASD 
symptoms (or autistic traits) and other behavioral, genetic, and neurobiological variables do not 
carefully take into account phenotypic characteristics, such as age, IQ, or EBP, as potential 
confounding factors.20-22 These practices have potentially very serious consequences, as they 
increase the likelihood of drawing erroneous conclusions about associations between ASD 
symptoms and etiological mechanisms.12  
Another implication of these findings is that when large-scale research studies of ASD (e.g., 
Simons Simplex Collection, SSC) base inclusion/exclusion criteria on classifications from ASD 
measures, research samples could become biased toward children who are more likely to meet 
standardized instrument cut-offs (e.g., those with lower IQ and/or more emotional/behavioral 
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problems). This could potentially exaggerate differences between research samples and clinical or 
general population samples of children with ASD. In the current sample, a post-hoc linear 
regression analysis showed that meeting SSC inclusion criteria was significantly associated with 
having more parent-rated internalizing problems (p<0.01) and clinician-observed 
emotional/behavioral problems (p<0.01) (parent-rated externalizing problems p=0.07; IQ p=0.11).   
The results of this study should be interpreted in light of relevant methodological factors. 
The influence of IQ and EBP on the discriminative ability of ASD symptom measures was 
examined in the context of clinical best-estimate diagnosis. Thus, although total/algorithm scores 
from the SRS, ADI-R and ADOS were not calculated, information elicited from these instruments 
(and all other information from the assessment) was considered in the diagnostic decision making 
process. On the other hand, keeping clinicians blind to other diagnostic information while they were 
rating the ADI-R and ADOS (including assigning separate clinicians to administer these measures 
whenever possible), ensuring that clinicians were blind to ASD instrument total scores and 
classifications while making best-estimate diagnoses, and continuously checking and maintaining 
reliability on the instruments within and across sites throughout the study period, are significant 
methodological strengths.   
The sample consisted of 2-13 year old children who had been recruited based on identified 
ASD or another neurodevelopmental disorder. The parents of participants received compensation 
for their time and a report from a comprehensive diagnostic evaluation that was free of charge, and 
this could have contributed to self-selection bias. Future studies should examine the generalizability 
of these findings to children of different ages or those recruited in other ways (e.g., 
epidemiologically ascertained or exclusively clinic referred samples). Given the small number of 
non-ASD participants with intellectual disabilities and mood and anxiety disorders, replication is 
particularly warranted in these groups. Importantly, differences in the score ranges of the ASD and 
emotional/behavioral problem measures could have contributed to variable power to detect 
associations with child characteristics. It is also likely that there are reciprocal relationships 
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between ASD symptoms and impairments of intellectual, emotional and behavioral functioning; 
longitudinal studies will be particularly useful in elucidating these relationships across 
development.  
Taken together, results of this study indicate that ASD symptom measures capture far more 
than symptoms of ASD. Elevated scores on these measures can reflect impairments in behavioral 
dimensions other than the social-communication deficits and repetitive behaviors they were 
designed to capture. The findings underscore the need to carefully consider factors not specific to 
ASD, including IQ and behavior problems, in analyses of ASD symptom measures in clinical and 
research settings. Overlooking these factors in genetic and neurobiological research studies places 
the field at risk for drawing incorrect conclusions about etiological and phenotypic relationships 
relevant to ASD and other neurodevelopmental disorders. As ASD symptom measures are adopted 
for wider use and applied to the study of populations not necessarily represented in the original 
validation samples, it is essential that clinicians and researchers take appropriate precautions to 
ensure valid interpretation of scores.  
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Tables 
Table 1: Sample characteristics [range] 
 
ASD (n=225) Other diagnoses (n=163) 
Male, n (%) 175 (77.78) 
 
111 (68.1)  
Female, n (%) 50 (22.22) 
 
52 (31.9)  
Age in years, m (SD) 7.04 (3.06) [2-13] 7.57 (2.87) [2-13] 
Maternal educationa: ≥ Some college, n (%) 179 (87.32)  129 (86)  
White racea, n (%) 168 (74.67)  96 (59.26)  
Language level (ADOS module)     
Nonverbal or Single words, n (%)  69 (30.67)  14 (8.59)  
Phrase-speech, n (%) 37 (16.44)  33 (20.25)  
Complex sentences, n (%) 119 (52.89)  116 (71.17)  
Verbal IQ, m (SD) 75.72 (31.39) [10-139] 91.66 (22.02) [14-157] 
Nonverbal IQ, m (SD) 82.25 (27.45) [12-141] 93.09 (20.21) [19-150] 
CBCL Internalizing T, m (SD) 62.5 (10.6) [33-87] 59.06 (12.03) [29-84] 
Clinical range, n (%) 117 (52)  68 (41.72)  
CBCL Externalizing T, m (SD) 60.78 (12.32) [33-97] 59.09 (12.38) [28-85] 
Clinical range, n (%) 88 (39.11)  54 (33.13)  
EBP-ADOS total, m (SD) 1.02 (1.02) [0-4] 0.99 (0.94) [0-4] 
Marked (≥2), n (%) 55 (24.44)  43 (26.38)  
Medication usea, n (%) 50 (23.92)  50 (34.72)  
Vineland adaptive composite, n (%) 76.41 (14.48) [38-117] 86.14 (13.34) [43-118] 
SRS raw (age ≥4 years)b, m (SD) 100.54 (29.9) [24-161] 69.2 (31.88) [11-161] 
SRS T (age ≥4 years)b, m (SD) 77.52 (12.49) [46-105] 65.1 (12.96) [41-101] 
ADI-current, m (SD) 27.77 (10.47) [5-53] 12.35 (8.93) [0-41] 
ADI-diagnostic, m (SD) 36.9 (12.39) [9-64] 17.61 (11.53) [1-57] 
ADOS raw, m (SD) 15.11 (5.41) [1-26] 4.52 (3.76) [0-23] 
ADOS CSS, m (SD) 7.25 (2.02) [1-10] 2.56 (1.97) [1-10] 
Note: ASD=autism spectrum disorder, CBCL=Child Behavior Checklist, SRS=Social Responsiveness Scale, ADI=Autism 
Diagnostic Interview-Revised, ADOS=Autism Diagnostic Observation Schedule, CSS=calibrated severity scores, standardized by 
age and language level. EBP-ADOS=clinician-observed emotional/behavioral problems, aMissing: maternal education n=33, race 
n=1, medication use n=35. bSRS: n=177 ASD, Other diagnoses n=142.  
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Table 2: Results of the multiple linear regression analyses using child characteristics as predictors of ASD 
instrument thresholds (SRS, ADI-R and ADOS) 
Child characteristics 
SRS Raw ADI-R Current ADOS Raw 
B (95% CI) B (95% CI) B (95% CI) 
IQ (NVIQ) -0.50*** (-0.68,-0.31) -0.08* (-0.14,-0.01) -0.03 (-0.06,0.01) 
Parent-rated EBP 
      
CBCL-Internalizing 1.08*** (0.68,1.48) 0.22*** (0.09,0.34) -0.05 (-0.11,0.01) 
CBCL-Externalizing 1.00*** (0.62,1.38) 0.13* (0.02,0.25) 0.02 (-0.03,0.07) 
Clinician-observed 
EBPa 
-0.05 (-4.85,4.75) 0.53 (-0.99,2.05) 0.89* (0.17,1.62) 
Sex (female) -6.17 (-14.21,1.88) -1.53 (-3.92,0.86) -0.90 (-2.02,0.23) 
Age (years) -0.43 (-1.96,1.11) -1.02*** (-1.49,-0.55) -0.19 (-0.41,0.03) 
Constant 75.58*** (70.76,80.40) 14.27*** (12.62,15.93) 4.99*** (4.27,5.70) 
R2 0.53 0.29 0.16 
n (all non-ASD) 142 163 163 
Note: NVIQ=nonverbal IQ, CBCL=Child Behavior Checklist, EBP=emotional/behavioral problems, SRS=Social Responsiveness 
Scale, ADI-R=Autism Diagnostic Interview-Revised, ADOS=Autism Diagnostic Observation Schedule. a ADOS “Other Abnormal 
Behaviors” section total. The SRS was included for children aged ≥4y. * p<0.05, ** p<0.01, *** p<0.001 (raw p values). 
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Table 3: Results of the ROC regression analyses using child characteristics as predictors of discriminative ability 
when adjusting for their influence on instrument thresholds 
Child characteristics 
SRS Raw ADI-R Current ADOS Raw 
B (95% CI) B (95% CI) B (95% CI) 
IQ (NVIQ) 0.01 (-0.00,0.02) <0.01 (-0.01,0.01) -0.01 (-0.02,0.01) 
Parent-rated EBP 
      
CBCL-Internalizing 0.01 (-0.02,0.04) 0.03 (-0.00,0.06) <0.01 (-0.05,0.04) 
CBCL-Externalizing -0.02 (-0.04,0.01) -0.01 (-0.04,0.02) <0.01 (-0.04,0.03) 
Clinician-observed 
EBPa 
-0.03 (-0.33,0.28) -0.02 (-0.27,0.22) 0.12 (-0.15,0.39) 
Sex (female) 0.62 (-0.04,1.28) 0.06 (-0.50,0.62) -0.26 (-0.93,0.42) 
Age (years) 0.10 (-0.02,0.22) 0.12** (0.04,0.21) 0.04 (-0.07,0.15) 
Constant - Intercept  0.85*** (0.51,1.19) 1.48*** (1.11,1.85) 2.71*** (1.92,3.51) 
Constant - Slope  1.10*** (0.84,1.35) 0.98*** (0.71,1.24) 1.26*** (0.68,1.84) 
n Non-ASD 142 163 163 
n ASD 177 225 225 
Note: NVIQ=nonverbal IQ, CBCL=Child Behavior Checklist, EBP=emotional/behavioral problems, SRS=Social Responsiveness 
Scale, ADI-R=Autism Diagnostic Interview-Revised, ADOS=Autism Diagnostic Observation Schedule. a ADOS “Other Abnormal 
Behaviors” section total. The SRS was included for children aged ≥4y. * p<0.05, ** p<0.01, *** p<0.001 (raw p values). 
 
  
  
 
26 
Table 4: Discriminative ability of the ASD instruments by representative levels of intellectual ability and 
emotional/behavioral problems (95% confidence intervals)  
Social Responsiveness Scale (SRS) 
Stratification 
n AUC Moderate cut-off (T≥66) 
ASD Other SRS-raw Sensitivity,% Specificity,% 
Total sample 177 142 0.76 (0.71,0.81) 84 (78,89) 58 (49,66) 
Intellectual disability 
Yes 55 26 0.73 (0.60,0.85) 93 (82,98) 27 (12,48) 
No 122 116 0.76 (0.70,0.82) 80 (72,87) 65 (55,73) 
CBCL-Internalizing: Clinical 
Yes 96 62 0.74 (0.66,0.82) 96 (90,99) 36 (24,49) 
No 81 80 0.78 (0.71,0.85) 70 (59,80) 75 (64,84) 
CBCL-Externalizing: Clinical 
Yes 73 49 0.74 (0.66,0.83) 96 (89,99) 39 (25,54) 
No 104 93 0.78 (0.71,0.84) 76 (67,84) 68 (57,77) 
EBP-ADOS: Marked 
Yes 41 34 0.72 (0.61,0.84) 93 (80,99) 41 (25,59) 
No 136 108 0.77 (0.71,0.83) 82 (74,88) 63 (53,72) 
Autism Diagnostic Interview-Revised (ADI-R) 
 
n AUC ADI-R ASD criteria 
ASD Other ADI-current Sensitivity,% Specificity,% 
Total sample 225 163 0.86 (0.82,0.89) 86 (81,90) 66 (58,74) 
Intellectual disability 
Yes 72 26 0.85 (0.77,0.94) 89 (79,95) 42 (23,63) 
No 153 137 0.85 (0.81,0.89) 84 (78,90) 71 (62,78) 
CBCL-Internalizing: Clinical Yes 117 68 0.86 (0.80,0.92) 94 (88,98) 59 (46,71) 
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No 108 95 0.85 (0.80,0.90) 77 (68,84) 72 (61,80) 
CBCL-Externalizing: Clinical 
Yes 88 54 0.85 (0.78,0.92) 92 (84,97) 56 (41,69) 
No 137 109 0.86 (0.82,0.91) 82 (74,88) 72 (62,80) 
EBP-ADOS: Marked 
Yes 55 43 0.80 (0.71,0.88) 91 (80,97) 51 (36,67) 
No 170 120 0.88 (0.84,0.92) 84 (78,89) 72 (63,80) 
Autism Diagnostic Observation Schedule (ADOS) 
 
n AUC ADOS ASD criteria 
ASD Other ADOS-raw Sensitivity,% Specificity,% 
Total sample 225 163 0.93 (0.91,0.96) 95 (91,97) 76 (69,82) 
Intellectual disability 
Yes 72 26 0.96 (0.93,0.99) 96 (88,99) 77 (56,91) 
No 153 137 0.92 (0.89,0.95) 94 (89,97) 76 (68,83) 
CBCL-Internalizing: Clinical  
Yes 117 68 0.93 (0.89,0.96) 93 (87,97) 78 (66,87) 
No 108 95 0.95 (0.92,0.98) 96 (91,99) 75 (65,83) 
CBCL-Externalizing: Clinical  
Yes 88 54 0.93 (0.89,0.97) 91 (83,96) 76 (62,87) 
No 137 109 0.94 (0.91,0.97) 97 (93,99) 76 (67,84) 
EBP-ADOS: Marked 
Yes 55 43 0.94 (0.89,0.99) 100 (94,100) 56 (40,71) 
No 170 120 0.95 (0.92,0.97) 93 (88,96) 83 (75,90) 
Note: AUC=area under the curve, SRS=Social Responsiveness Scale, ADI-R=Autism Diagnostic Interview-Revised, ADOS=Autism 
Diagnostic Observation Schedule, CBCL=Child Behavior Checklist. See Table S3 for sensitivity/specificity of alternative cut-offs.  
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Figures 
Figure 1 (A, B, C): Box-plot diagrams showing the distributions of autism symptom scores for children with and 
without autism spectrum disorder (ASD) by level of emotional/behavioral problems (EBP), and effect sizes of the mean 
differences between diagnostic groups (non-ASD versus ASD).  
 
Note: ASD=autism spectrum disorder, SRS=Social Responsiveness Scale, ADI=Autism Diagnostic Interview-Revised, 
ADOS=Autism Diagnostic Observation Schedule, Parent-rated EBP=Child Behavior Checklist Externalizing or 
Internalizing scale in clinical range (T≥64). Clinician-observed EBP=ADOS Other Abnormal Behaviors section. 
ES=effect size (partial eta squared),*p<0.05, ** p<0.01, *** p<0.001. 
A:       B:  
 
 
C:  
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Supplementary material 
 
Table S1: Co-occurring diagnoses 
Table S2: Bivariate associations (Pearson´s correlations) among the child characteristics and the 
ASD symptom measures (SRS, ADI-R, ADOS) 
Table S3: Discriminative ability of the ASD instruments by representative levels of intellectual 
ability and emotional/behavioral problems  
Figure S1: Box-plot diagrams showing the distributions of autism symptom scores for children 
with and without autism spectrum disorder (ASD) by level of emotional/behavioral problems 
(EBP), and effect sizes of the mean differences between diagnostic groups (non-ASD versus ASD).  
Table S1: Co-occurring diagnoses, n (%) 
  Primary diagnosis 
ASD 
 
Intellectual 
disability 
ADHD 
Language 
disorder 
Anxiety/ 
mood disorder 
Intellectual disability 35 (15.56) - 0 0 0 
ADHD 38 (16.89) 6 (23.08) - 1 (2.08) 5 (18.52) 
Language disorder 38 (16.89) 8 (30.77) 8 (12.90) - 1 (3.70) 
Anxiety/mood disorder 4 (1.78) 0 4 (6.45) 2 (4.17) - 
Other  8 (3.56) 3 (11.54) 7 (11.29) 2 (4.17) 1 (3.70) 
No co-occurring  
diagnosis 
102 (45.33) 9 (34.62) 43 (69.35) 43 (89.58) 20 (74.07) 
Total 225 (100.00) 26 (100.00) 62 (100.00) 48 (100.00) 27 (100.00) 
Note: ASD=autism spectrum disorder, ADHD=attention deficit/hyperactivity disorder. 
  
  
 
30 
 
Table S2: Bivariate associations (Pearson´s correlations) among the child characteristics and the autism symptom 
measures (SRS, ADI-R, ADOS) 
Non-ASD 
(n=163) 
IQ 
(NVIQ) 
CBCL-
Int 
CBCL-
Ext 
EBP-
ADOS 
Age, y Sex (F) SRSa ADI-R ADOS 
IQ (NVIQ) 1 
        
CBCL-Int -0.06 1 
       
CBCL-Ext -0.08 0.58*** 1 
      
EBP-ADOS -0.18* 0.04 0.19* 1 
     
Age, y -0.21** 0.21** 0.11 -0.28*** 1 
    
Sex (F) -0.05 -0.04 -0.06 -0.13 0.08 1 
   
SRSa -0.27** 0.57*** 0.59*** 0.20* 0.07 -0.08 1 
  
ADI-R -0.14 0.35*** 0.35*** 0.24** -0.23** -0.13 0.60*** 1 
 
ADOS -0.15 -0.11 0.03 0.31*** -0.21** -0.14 0.05 0.29*** 1 
ASD 
(n=225) 
IQ 
(NVIQ) 
CBCL-
Int 
CBCL-
Ext 
EBP-
ADOS 
Age, y Sex (F) SRSa ADI-R ADOS 
IQ (NVIQ) 1 
        
CBCL-Int 0.13 1 
       
CBCL-Ext -0.01 0.61*** 1 
      
EBP-ADOS -0.16* 0.06 0.12 1 
     
Age, y 0.16* 0.15* -0.07 -0.20** 1 
    
Sex (F) -0.04 0.14* 0.20** -0.05 0.04 1 
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SRSa -0.23** 0.57*** 0.53*** 0.05 0.12 0.21** 1 
  
ADI-R -0.16* 0.45*** 0.39*** 0.1 0.04 0.12 0.67*** 1 
 
ADOS -0.50*** -0.18** -0.11 0.23*** -0.17** -0.17* 0.09 0.23*** 1 
Note: NVIQ=nonverbal IQ, CBCL=Child Behavior Checklist, Int=internalizing, Ext=externalizing, ADOS=Autism Diagnostic 
Observation Schedule (raw), SRS=Social Responsiveness Scale (raw), ADI=Autism Diagnostic Interview-Revised (current), EBP-
ADOS=clinician-observed emotional/behavioral problems (total of overactivity, aggressive behavior, and anxiety items).  a The SRS 
original version used is only appropriate for children aged 4 years and older (N=177 ASD, 142 non-ASD). *p<0.05, ** p<0.01, *** 
p<0.001. 
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Table S3: Discriminative validity of the instruments by level of IQ and emotional and behavior problems (95% 
confidence intervals)  
Instrument: SRS n AUC Cutoff specificity, % Cutoff sensitivity, % 
Stratification ASD Other SRS-raw Moderate Severe Moderate Severe 
Total 177 142 0.76 (0.71,0.81) 58 (49,66) 79 (71,85) 84 (78,89) 55 (47,62) 
Intellectual disability 55 26 0.73 (0.60,0.85) 27 (12,48) 69 (48,86) 93 (82,98) 66 (51,78) 
No intellectual disability 122 116 0.76 (0.70,0.82) 65 (55,73) 81 (73,88) 80 (72,87) 50 (41,60) 
CBCL-Int: Clinical 96 62 0.74 (0.66,0.82) 36 (24,49) 60 (46,72) 96 (90,99) 72 (62,81) 
CBCL-Int:< Clinical 81 80 0.78 (0.71,0.85) 75 (64,84) 94 (86,98) 70 (59,80) 35 (24,46) 
CBCL-Ext: Clinical 73 49 0.74 (0.66,0.83) 39 (25,54) 59 (44,73) 96 (89,99) 77 (65,86) 
CBCL-Ext:< Clinical 104 93 0.78 (0.71,0.84) 68 (57,77) 89 (81,95) 76 (67,84) 39 (30,50) 
EBP-ADOS: Marked 41 34 0.72 (0.61,0.84) 41 (25,59) 77 (59,89) 93 (80,99) 51 (35,67) 
EBP-ADOS: Little-to-no 136 108 0.77 (0.71,0.83) 63 (53,72) 80 (71,87) 82 (74,88) 56 (48,65) 
Instrument: ADI-R n AUC Cutoff specificity, % Cutoff sensitivity, % 
Stratification ASD Other ADI-current ASD Autism ASD Autism 
Total 225 163 0.86 (0.82,0.89) 66 (58,74) 83 (76,88) 86 (81,90) 73 (67,79) 
Intellectual disability 72 26 0.85 (0.77,0.94) 42 (23,63) 65 (44,83) 89 (79,95) 82 (71,90) 
No intellectual disability 153 137 0.85 (0.81,0.89) 71 (62,78) 86 (79,91) 84 (78,90) 69 (61,77) 
CBCL-Int: Clinical 117 68 0.86 (0.80,0.92) 59 (46,71) 72 (60,82) 94 (88,98) 86 (78,91) 
CBCL-Int:< Clinical 108 95 0.85 (0.80,0.90) 72 (61,80) 91 (83,96) 77 (68,84) 60 (50,70) 
CBCL-Ext: Clinical 88 54 0.85 (0.78,0.92) 56 (41,69) 76 (62,87) 92 (84,97) 83 (73,90) 
CBCL-Ext:< Clinical 137 109 0.86 (0.82,0.91) 72 (62,80) 86 (78,92) 82 (74,88) 67 (59,75) 
EBP-ADOS: Marked 55 43 0.80 (0.71,0.88) 51 (36,67) 67 (52,81) 91 (80,97) 84 (71,92) 
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EBP-ADOS: Little-to-no 170 120 0.88 (0.84,0.92) 72 (63,80) 88 (81,94) 84 (78,89) 70 (63,77) 
Instrument: ADOS n AUC Cutoff specificity, % Cutoff sensitivity, % 
Stratification ASD Other ADOS-raw ASD Autism ASD Autism 
Total 225 163 0.93 (0.91,0.96) 76 (69,82) 87 (81,92) 95 (91,97) 82 (76,87) 
Intellectual disability 72 26 0.96 (0.93,0.99) 77 (56,91) 89 (70,97) 96 (88,99) 86 (76,93) 
No intellectual disability 153 137 0.92 (0.89,0.95) 76 (68,83) 87 (80,92) 94 (89,97) 80 (73,86) 
CBCL-Int: Clinical 117 68 0.93 (0.89,0.96) 78 (66,87) 90 (80,96) 93 (87,97) 80 (71,86) 
CBCL-Int:< Clinical 108 95 0.95 (0.92,0.98) 75 (65,83) 85 (77,92) 96 (91,99) 84 (76,91) 
CBCL-Ext: Clinical 88 54 0.93 (0.89,0.97) 76 (62,87) 91 (80,97) 91 (83,96) 76 (66,85) 
CBCL-Ext:< Clinical 137 109 0.94 (0.91,0.97) 76 (67,84) 85 (77,91) 97 (93,99) 85 (78,91) 
EBP-ADOS: Marked 55 43 0.94 (0.89,0.99) 56 (40,71) 72 (56,85) 100 (94,100) 95 (85,99) 
EBP-ADOS: Little-to-no 170 120 0.95 (0.92,0.97) 83 (75,90) 93 (86,97) 93 (88,96) 78 (71,84) 
Note: AUC=area under the curve, SRS=Social Responsiveness Scale, ADI-R=Autism Diagnostic Interview-Revised, 
ADOS=Autism Diagnostic Observation Schedule, CBCL=Child Behavior Checklist, Int=Internalizing (clinical:≥64), 
Ext=Externalizing (clinical:≥64), EBP-ADOS=clinician-observed emotional/behavioral problems (marked:≥2).  
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Figure S1 (A, B, C): Box-plot diagrams showing the distributions of autism symptom scores for children with and 
without autism spectrum disorder (ASD) by level of emotional/behavioral problems (EBP).  
 
Note: ASD=autism spectrum disorder, SRS=Social Responsiveness Scale, ADI=Autism Diagnostic Interview-Revised, 
ADOS=Autism Diagnostic Observation Schedule, Parent-rated EBP=Child Behavior Checklist Externalizing or 
Internalizing scale in clinical range (T≥64). Clinician-observed EBP=ADOS Other Abnormal Behaviors section. 
ES=effect size (partial eta squared). *p<0.05, ** p<0.01, *** p<0.001. 
A:       B: 
  
C:  
 
